Clinical Report: Development of Gangrene Following Radiopharmaceutical Treatment
Overview
This report details a case of gangrene following a single dose of the investigational radiopharmaceutical Sn-117m-DTPA in a patient with extensive skeletal metastases from castration-resistant prostate cancer. The patient experienced significant complications, including leukopenia and sepsis, ultimately leading to death.
Background
Bone-seeking radiopharmaceuticals are commonly used for treating skeletal metastases, providing palliative benefits but also posing risks of serious radiation-related adverse events (rrAEs). Understanding these rare but severe complications is crucial for improving patient management and outcomes. This case highlights the need for vigilance in monitoring skin integrity and other potential adverse effects following radiopharmaceutical treatments.
Data Highlights
No numerical data or trial data presented in the article.
Key Findings
['An 80-year-old man developed gangrene 24 days after receiving Sn-117m-DTPA.', 'Laboratory tests indicated leukopenia at the time of gangrene onset.', 'Despite initial pain relief from skeletal metastases, the patient faced severe complications leading to amputation and subsequent sepsis.', 'Gangrene occurred late after treatment, emphasizing the need for prompt intervention.', 'Subtle skin integrity issues may be more common post-treatment than previously recognized.']
Clinical Implications
Healthcare professionals should be aware of the potential for serious adverse events, such as gangrene, following the administration of bone-seeking radiopharmaceuticals. Close monitoring of patients for signs of skin integrity issues and prompt intervention are essential to mitigate risks.
Conclusion
This case underscores the importance of recognizing and addressing rare but serious complications associated with radiopharmaceutical treatments in patients with skeletal metastases. Enhanced awareness and management strategies are necessary to improve patient safety.
